Prelude Capital Management, LLC Silverback Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	N/A	-1,436 Reduced 8.71%	15,053 $0
Q4 2022 Feb 14, 2023	SELL	$0.0 - $6.07 $0 - $19,454	-3,205 Reduced 16.27%	16,489 $0
Q3 2022 Nov 14, 2022	SELL	$3.91 - $5.52 $86,043 - $121,473	-22,006 Reduced 52.77%	19,694 $104,000
Q2 2022 Aug 15, 2022	BUY	$2.9 - $4.44 $22,330 - $34,188	7,700 Added 22.65%	41,700 $177,000
Q1 2022 May 16, 2022	BUY	$3.51 - $6.74 $60,722 - $116,602	17,300 Added 103.59%	34,000 $119,000

Q4 2021 Feb 14, 2022	BUY	$6.03 - $11.67 $100,701 - $194,889	16,700 New	16,700 $111,000

117

47.9M

442K

42K

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.